dr. shaw discusses the advent of more potent alk inhibitors
Published 10 years ago • 91 plays • Length 1:14Download video MP4
Download video MP3
Similar videos
-
1:51
dr. shaw on ldk378 in alk crizotinib-resistant nsclc patients
-
2:32
dr. shaw discusses ldk378 and alectinib (af802) for alk-positive nsclc
-
1:58
dr. shaw on crizotinib in alk-positive lung cancer
-
1:52
dr. shaw on crizotinib versus chemotherapy in alk-positive nsclc
-
2:26
dr. shaw on alectinib as first-line therapy in lung cancer
-
1:21
dr. shaw on crizotinib resistance in alk-positive lung cancer
-
39:36
targeting of nsclc in 2011 by alice shaw, md, phd
-
43:28
advances in targeted therapies for lung cancer - by alice t. shaw, md phd
-
6:41
next-generation alk inhibitors for nsclc
-
46:36
dr. shaw: alk-positive lung cancer presentation
-
42:31
alk positive lung cancer in 2023 and beyond: thinking outside the box with dr. alice shaw
-
6:27
alk inhibitor sequencing in nsclc
-
1:57
dr. shaw on sequencing strategies in alk-positive nsclc
-
6:02
shaw patterns of resistance in alk positive nsclc
-
1:38
dr. alice shaw describes ldk378 in alk-positive non-small cell lung cancer
-
4:23
efficacy of next-generation alk inhibitors in nsclc
-
26:57
segment 2: molecular targets in nsclc
-
40:53
alk and ros1 in lung cancer next generation targeted therapies
-
2:04
dr. shaw discusses lorlatinib in lung cancer